Based on data from a registry, clinical outcomes of 174 patients were analyzed in this study. With a median follow-up period 908 days, the 3-year OS rates for stage I, II and III were 84.8%, 60.3% and 42.9%; the 3-year PFS rates for stage I, II and III were 71.9%, 58.3% and 37.0%; and the 3-year LC were 78.4%, 79.8% and 65.2%, respectively. Four patients (2.3%) with ≥Grade 3 cardiopulmonary toxicities were observed. The authors concluded that this study showed lower rates of adverse cardiopulmonary events with particle therapy than photon radiotherapy.